All Topics
All Topics
Technology
Technology
AI
AI
Business
Business
Entertainment
Entertainment
News
News
Programming
Programming
Science
Science
Design
Design
Environment
Environment
Finance
Finance
Crypto
Crypto
Politics
Politics
Sports
Sports
Education
Education
Gaming
Gaming
Art
Art
Music
Music
Health
Health
Security
Security
Books
Books
Food
Food
Travel
Travel
Personal
Personal
Bluesky
Twitter

Research Spotlight: A New Era of Progress Against Pancreatic Cancer

May 27, 2026 - By Anna Berkenblit, MD, MMSc Editor’s note: The “Research Spotlight” series is written by Dr. Anna Berkenblit , PanCAN’s Chief Scientific and Medical Officer. Each month, Dr…

Read the full article

You might also wanna read

Experimental pill daraxonrasib extends survival in advanced pancreatic cancer patients, study finds

A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better tre

npr.org·1mo ago

Experimental daraxonrasib pill extends survival for advanced pancreatic cancer patients, study finds

An experimental pill helped people with one of the most deadly cancers in the world live longer, researchers reported this weekend.

fox26houston.com·1mo ago

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer | NEJM

Results of the earlier phase 1-2 study of 168 patients, published recently 🧪💊

nejm.org·1mo ago

Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial

A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better tre

chicagotribune.com·1mo ago

Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial

A novel pill helped people with advanced pancreatic cancer live longer, researchers reported Sunday, raising hopes of long-needed better tre

chicagotribune.com·1mo ago

Experimental daraxonrasib pill nearly doubles survival time in advanced pancreatic cancer trial

Those taking daraxonrasib lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients.

cnbc.com·1mo ago

Lab Study Finds Compound Stops 90% of Pancreatic Cancer Cell Migration

Pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer, is particularly deadly and hard to treat.

sciencealert.com·8d ago

Lab Study Finds Compound Stops 90% of Pancreatic Cancer Cell Migration

Pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer, is particularly deadly and hard to treat.

sciencealert.com·8d ago

Comments

Sign in to join the conversation.

No comments yet. Be the first.